Growth Accelerated By Increasing Product Pipeline For Postpartum Depression Treatment Market

Postpartum Depression Treatment Market 

The postpartum depression drug market comprises medications prescribed for treating postpartum depression, a type of mood disorder experienced by women after childbirth. Postpartum depression causes feelings of extreme sadness, anxiety, and exhaustion that may interfere with daily activities and the ability to care for a newborn. The growing awareness regarding postpartum depression and supportive government initiatives are encouraging more women to seek treatment. The global Postpartum Depression Drug Market is estimated to be valued at US$ 7.67 Bn in 2023 and is expected to exhibit a CAGR of 26% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
An increasing number of drugs in the pipeline for postpartum depression is one of the major trends witnessed in the market. Several pharmaceutical companies are conducting clinical trials to develop safe and effective drugs for postpartum depression. For instance, Sage Therapeutics is evaluating SAGE-217, a neuroactive steroid GABA-A modulator, in a Phase 3 clinical trial for major depressive disorder and postpartum depression. If approved, SAGE-217 will be the first non-hormonal therapy approved by the FDA for postpartum depression. Such developments in the product pipeline are expected to drive the market growth over the forecast period.

Segment Analysis
The global postpartum depression drug market is dominated by the selective serotonin reuptake inhibitors (SSRIs) segment. SSRIs are the commonly prescribed drugs for postpartum depression as they are considered safe for breastfeeding women. Drugs from this segment such as sertraline and paroxetine are the most preferred by doctors owing to their effectiveness and low risk of transfer into breast milk.

Key Takeaways
The global Postpartum Depression Drug Market is expected to witness high growth during the forecast period of 2024 to 2031. The market is projected to grow from US$ 7.67 Bn in 2024 to reach US$ 29.76 Bn by 2031, expanding at a CAGR of 26%.

Regional analysis: North America is currently the dominant region for the postpartum depression drug market owing to factors such as rising awareness about postpartum depression, easy availability of drugs, and favorable reimbursement policies. The United States holds the largest share in the regional market and is expected to retain its position during the forecast period driven by ongoing research efforts to develop safer and effective treatments.

Key players operating in the postpartum depression drug market are Salesforce.com Inc., Appian Corporation, Microsoft Corporation, Magic Software Enterprises Ltd, Pegasystems Inc., Oracle Corporation, ZOHO Corporation, Mendix Inc. (Siemens AG), AgilePoint Inc., QuickBase Inc., Clear Software LLC (Microsoft Corporation), ServiceNow Inc., Skuid Inc., Outsystems Inc., Temenos AG.

For more insights, read- https://www.newsstatix.com/postpartum-depression-drug-market-trends-size-and-share-analysis/

For more details on the report, Read- https://dailynewsmotion.weebly.com/report-blog/plant-based-meat-market-is-estimated-to-witness-high-growth-owing-to-opportunity